[go: up one dir, main page]

ECSP13012551A - Terapia de combinación para tratar infección por hcv. - Google Patents

Terapia de combinación para tratar infección por hcv.

Info

Publication number
ECSP13012551A
ECSP13012551A ECSP13012551A ECSP13012551A EC SP13012551 A ECSP13012551 A EC SP13012551A EC SP13012551 A ECSP13012551 A EC SP13012551A EC SP13012551 A ECSP13012551 A EC SP13012551A
Authority
EC
Ecuador
Prior art keywords
hcv infection
combination therapy
treat hcv
compound
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
George Kukolj
Wulf Boecher
Carla Haefner
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP13012551A publication Critical patent/ECSP13012551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a combinaciones terapéuticas que comprenden (a) Compuesto (1) o una sal farmacéuticamente aceptable del mismo, como se describe en la presente memoria, (b) Compuesto (2) o una sal farmacéuticamente aceptable del mismo, como se describe en la presente memoria y opcionalmente (c) ribavirina y métodos para usar tales combinaciones terapéuticas para el tratamiento de la infección por HCV o mejorar uno o más síntomas de la misma en un paciente.
ECSP13012551 2010-09-30 2013-04-15 Terapia de combinación para tratar infección por hcv. ECSP13012551A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38825310P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
ECSP13012551A true ECSP13012551A (es) 2013-06-28

Family

ID=44735903

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012551 ECSP13012551A (es) 2010-09-30 2013-04-15 Terapia de combinación para tratar infección por hcv.

Country Status (21)

Country Link
US (1) US20120135949A1 (es)
EP (1) EP2621495A1 (es)
JP (1) JP2013540112A (es)
KR (1) KR20130116245A (es)
CN (1) CN103228278A (es)
AP (1) AP2013006734A0 (es)
AU (1) AU2011310761A1 (es)
BR (1) BR112013007423A2 (es)
CA (1) CA2813093A1 (es)
CL (1) CL2013000670A1 (es)
CO (1) CO6700843A2 (es)
EA (1) EA201300421A1 (es)
EC (1) ECSP13012551A (es)
MA (1) MA34547B1 (es)
MX (1) MX2013003060A (es)
PE (1) PE20131397A1 (es)
PH (1) PH12013500559A1 (es)
SG (1) SG188238A1 (es)
TW (1) TW201306839A (es)
WO (1) WO2012041771A1 (es)
ZA (1) ZA201300992B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013147749A1 (en) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7027A (en) * 1850-01-15 Circulak
US10006A (en) * 1853-09-06 Improvement in printer s ink
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EA009295B1 (ru) 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
EP1651631A1 (en) * 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
CN103319464A (zh) * 2004-02-20 2013-09-25 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
AU2006213769B2 (en) 2005-02-11 2012-10-04 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
AU2006261132A1 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
US20070032488A1 (en) * 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
WO2009021121A2 (en) * 2007-08-08 2009-02-12 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
AU2009293494B2 (en) 2008-09-16 2014-04-24 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR073603A1 (es) * 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
AU2009316755B2 (en) 2008-11-21 2015-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition of a potent HCV inhibitor for oral administration
UA104195C2 (ru) 2009-07-07 2014-01-10 Берингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция ингибитора протеазы вируса гепатита c

Also Published As

Publication number Publication date
TW201306839A (zh) 2013-02-16
CL2013000670A1 (es) 2013-08-09
JP2013540112A (ja) 2013-10-31
EP2621495A1 (en) 2013-08-07
MX2013003060A (es) 2013-05-30
ZA201300992B (en) 2014-07-30
CO6700843A2 (es) 2013-06-28
SG188238A1 (en) 2013-04-30
BR112013007423A2 (pt) 2016-07-12
PH12013500559A1 (en) 2013-05-06
EA201300421A1 (ru) 2013-08-30
AU2011310761A1 (en) 2013-02-21
PE20131397A1 (es) 2014-01-04
US20120135949A1 (en) 2012-05-31
CN103228278A (zh) 2013-07-31
CA2813093A1 (en) 2012-04-05
MA34547B1 (fr) 2013-09-02
WO2012041771A1 (en) 2012-04-05
KR20130116245A (ko) 2013-10-23
AP2013006734A0 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
UY32124A (es) Terapia combinada para tratar infección por hcv
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
CR20140086A (es) Tratamientos de combinación para hepatitis c
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
PH12014500832A1 (en) Methods for treating hcv
NI201100077A (es) Terapia de combinación con epoxicetonas peptídicas.
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
UY33797A (es) Composiciones farmacéuticas para el tratamiento del vhc
AR101740A1 (es) Terapia de combinación y composiciones
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
EA021554B9 (ru) Органические соединения и их применение для лечения hcv инфекции
MX362098B (es) El uso de células derivadas de tejido del cordón umbilical y kits que contienen las mismas para el tratamiento de enfermedad vascular periférica.
BR112012010110A2 (pt) regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
DOP2014000030A (es) Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
TN2013000134A1 (en) Combination therapy for treating hcv infection
UY34020A (es) Terapia combinada para tratar la infección por vhc en una población de pacientes co-infectados por vhc-vih
AR086186A1 (es) Terapia combinada oral para tratar infeccion por hcv en una poblacion de subgenotipos de pacientes especificos, kit y compuesto
CU20110091A7 (es) Terapia de combinación con epoxicetonas peptídicas
AR086185A1 (es) Terapia combinada oral para tratar infeccion por hcv en una subpoblacion de pacientes especificos